Stereotaxis, Inc.
HealthcareAMEX:STXS · New York Stock Exchange American
+$0.02 today
Vol 0.19M · Avg 0.39M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$31.2M of revenue converted into -$21.7M of net income for the selected period. Gross margin is 54.3% and net margin is -71.8%, showing how much revenue survives after costs and taxes. EPS is $-0.24, tying the income statement back to per-share earnings.
Income Statement
Annual data · 0 periods
| Metric |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Margin |
| Research & Development |
| Selling, General & Admin |
| Operating Expenses |
| Depreciation & Amortization |
| EBITDA |
| EBITDA Margin |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income / Expenses |
| Income Before Tax |
| Pre-Tax Margin |
| Income Tax Expense |
| Net Income |
| Net Margin |
| EPS (Basic) |
| EPS (Diluted) |
| Weighted Avg Shares |
| Weighted Avg Shares (Diluted) |
Competitors
Peer companies in the same sector
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Sanara MedTech Inc.
NASDAQ:SMTI
$190.70M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Quanterix Corporation
QTRX
$146.03M
CVRx, Inc.
CVRX
$133.48M
Exagen Inc.
XGN
$112.83M
MDxHealth S.A.
MDXH
$27.85M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does STXS generate?
Stereotaxis, Inc. (STXS) reported $32.38M of revenue in fiscal 2025.
Is STXS profitable?
Stereotaxis, Inc. (STXS) reported -$21,643,000.00 of net income, with a net margin of -66.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.